Roche’s Virtual AAN Investor Event
The virtual event has finished, the replay will be available soon.
| Agenda | |
|---|---|
| Introduction | Bruno Eschli, Head of Investor Relations |
| Fenebrutinib development overview | Alexandra Goodyear, Lifecycle Leader Fenebrutinib |
| Ph III (FENhance 1/2) fenebrutinib vs. Aubagio in RMS | Jiwon Oh, MD, PhD, FRCPC, Medical Director, Barlo Multiple Sclerosis Program, Associate Professor, Division of Neurology, St. Michael’s Hospital, University of Toronto, Staff Neurologist, St. Michael’s Hospital, Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute |
| Q&A |
Investors